The International Osteoporosis Foundation (IOF) states that osteoporosis results in more than 8.9 million fractures each year. It also forecasts that the global incidence of hip fracture in women and men will increase by 240% and 310%, respectively, by 2050, compared to the rates recorded in 1990. The organization also states that over 50% of all osteoporotic hip fractures will be recorded in Asia, by 2050, and nearly 5.34 million osteoporotic fractures will be registered in Europe by 2034.
Furthermore, the World Health Organization (WHO) estimates that this disease affects nearly 21.2% of the global female population aged over 50 years and around 6.3% global male population in the same age group. The rising prevalence of osteoporosis and the mushrooming geriatric population are, therefore, expected to drive the osteoporosis market at a CAGR of 3.8% during the forecast years (2016–2022). According to P&S Intelligence, the market was valued at $8,835.4 million in 2015, and it will generate $11,482.1 million revenue by 2022.
The drug class segment of the osteoporosis market is classified into bisphosphonates, calcitonin, parathyroid hormone therapy, rank ligand inhibitor, selective estrogen receptor modulator (SERM), and others. Under this segment, the bisphosphonates category accounted for the largest market share in 2015. Whereas, the rank ligand inhibitor category is expected to demonstrate the fastest growth during the forecast period. The rising use of these drugs can be attributed to the soaring public awareness about osteoporosis and its treatment.
In contemporary years, the North American region consumes the maximum volume of osteoporosis drugs due to the high prevalence of this bone disease and a vast population of old people. The U.S. Department of Health and Human Services states that nearly 12.6% of the U.S. populace were living with osteoporosis during 2017–2018. As per this department, 8.4% of the population aged 50–64 years and 17.7% people aged 65 years and more were affected by osteoporosis in the U.S. in the said time.